Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for moderate-to-severe rotator cuff tendinopathy
CTR20231325Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in shoulder tendinopathy, sponsored by Novartis. Started May 2023; status: terminated.
02
Drugs
secukinumab
03
Conditions
shoulder tendinopathy
Beyond the preview
Go deeper on CTR20231325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231325.